Clinical Trials Browser

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Transitional Cell

Neoplasm Metastasis

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

Lung Neoplasms, Small Cell Lung Carcinoma

Glioblastoma

Carcinoma, Transitional Cell

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Head and Neck Neoplasms

Salivary Gland Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Metastatic Urothelial Cancer

Urothelial Bladder Carcinoma

Ovarian Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms

Breast Neoplasms

Cholangiocarcinoma, Klatskin Tumor

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Endometrial Neoplasms

Carcinoma, Non-Small-Cell Lung

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Triple Negative Breast Neoplasms

Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Triple Negative Breast Neoplasms

Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Breast Cancer Metastatic

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

Salivary Gland Neoplasms, Thyroid Neoplasms

Breast Neoplasms

Lung Neoplasms

Clinical Trials

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

InCITe

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Sacituzumab Govitecan in Recurrent Glioblastoma

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

TianjinCIH

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

VELOCITY-Lung

TROPHY U-01

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

EVOKE-02

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

TROPiCS-03

SATROPIN

STORM

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

ADJUNCT

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

SERIES

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

PRIMED

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Scalp Cooling in MBC

Study of Sacituzumab Govitecan in Patients With Solid Tumor

ELEVATE TNBC

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

NeoSTAR

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

ALTER

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

TROP2

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer